Autres langues Neumora Therapeutics, Inc.

Actions

NMRA

US6409791000

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/06/2024			Varia. 5j.	Varia. 1 janv.
9,38 ^USD	-4,09%		-9,98%	-44,99%

14/05	Transcript : Neumora Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM
14/05	Neumora Therapeutics, Inc. annonce le lancement d'une étude de phase 2 sur le navacaprant dans la dépression bipolaire	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	14/05
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	14/05
Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	14/05
Neumora Therapeutics Shares Fall as Q1 Loss Narrows	07/05
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	07/05
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Neumora Therapeutics to Participate in Upcoming Conferences in May	06/05
Sector Update: Health Care Stocks Advance Premarket Monday	15/04
Sector Update: Health Care	15/04
Investors Shrug Off Geopolitical Concerns, Driving Premarket Gains for US Equity Futures	15/04
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	15/04
Top Premarket Decliners	15/04
Neumora Therapeutics' Phase 1 Trial of Potential Brain Disease Drug on Hold After Convulsions in Rabbits	15/04
Neumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on Hold	15/04
Neumora's early-stage schizophrenia drug study put on hold	15/04
U.S. FDA places clinical hold on Neumora's schizophrenia drug study	15/04
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	15/04
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	15/04
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to S&P Global BMI Index	18/03
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days	13/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Neumora Therapeutics, Inc.

Actions

NMRA

US6409791000

Autres langues

Filtres